{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:06:51Z","timestamp":1776355611309,"version":"3.51.2"},"update-to":[{"DOI":"10.1016\/j.vascn.2026.108419","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000}}],"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vascn.2026.108419","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:17:15Z","timestamp":1772731035000},"page":"108419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["WITHDRAWN: Simultaneous quantification of venetoclax, busulfan and voriconazole in plasma by LC-MS\/MS: clinical applications in patients with acute myeloid leukemia"],"prefix":"10.1016","author":[{"given":"Zhenhua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingchen","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changrui","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2026.108419_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsps.2023.06.026","article-title":"LC-MS\/MS method for the quantitation of decitabine and venetoclax in rat plasma after SPE: Application to pharmacokinetic study","volume":"31","author":"Alnasser","year":"2023","journal-title":"Saudi Pharmaceutical Journal"},{"key":"10.1016\/j.vascn.2026.108419_bb0010","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/biomedicines11020530","article-title":"Development and validation of a novel LC-MS\/MS method for a TDM-guided personalization of HSCT conditioning with high-dose busulfan in children","volume":"11","author":"Cafaro","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.vascn.2026.108419_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.htct.2024.02.028","article-title":"Microcosting analysis of haematopoietic stem cell transplantation and chemotherapy with intermediate doses of cytarabine in the treatment of acute myeloid leukaemia","author":"Chiesa","year":"2024","journal-title":"Hematology, Transfusion and Cell Therapy"},{"key":"10.1016\/j.vascn.2026.108419_bb0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/17474086.2023.2192918","article-title":"Current therapies for chronic lymphocytic leukemia: Risk and prophylaxis strategies for secondary\/opportunistic infections","volume":"16","author":"Diella","year":"2023","journal-title":"Expert Review of Hematology"},{"key":"10.1016\/j.vascn.2026.108419_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122176","article-title":"Development and validation of a sensitive UHPLC-MS\/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies","volume":"1152","author":"Eisenmann","year":"2020","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"10.1016\/j.vascn.2026.108419_bb0030","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/jjco\/hyad075","article-title":"Safety and efficacy of venetoclax for acute myeloid leukaemia in real-world clinical practice","volume":"53","author":"Fukumoto","year":"2023","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1016\/j.vascn.2026.108419_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115279","article-title":"Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS\/MS and its application in acute myeloid leukemia patients","volume":"227","author":"Gao","year":"2023","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.vascn.2026.108419_bb0040","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1182\/bloodadvances.2021005566","article-title":"Adding venetoclax to fludarabine\/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active","volume":"5","author":"Garcia","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/j.vascn.2026.108419_bb0045","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","article-title":"Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML","volume":"8","author":"Garcia","year":"2024","journal-title":"Blood Advances"},{"key":"10.1016\/j.vascn.2026.108419_bb0050","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10156-011-0363-6","article-title":"Investigation and threshold of optimum blood concentration of voriconazole: A descriptive statistical meta-analysis","volume":"18","author":"Hamada","year":"2012","journal-title":"Journal of Infection and Chemotherapy"},{"key":"10.1016\/j.vascn.2026.108419_bb0070","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s11739-023-03517-z","article-title":"Deciphering cytopenias in internal medicine: A single-center observational study","volume":"19","author":"Leoni","year":"2024","journal-title":"Internal and Emergency Medicine"},{"key":"10.1016\/j.vascn.2026.108419_bb0075","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jconrel.2023.05.009","article-title":"Recent advances in biomimetic nanodelivery systems: New brain-targeting strategies","volume":"358","author":"Liao","year":"2023","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.vascn.2026.108419_bb0080","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1080\/10428194.2022.2068006","article-title":"Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia","volume":"63","author":"Machherndl-Spandl","year":"2022","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.vascn.2026.108419_bb0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/jcph.2140","article-title":"Impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics: A PBPK and population PK-informed analysis","volume":"63","author":"Mukherjee","year":"2023","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2026.108419_bb0090","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41409-018-0281-7","article-title":"Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: A pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children","volume":"54","author":"Philippe","year":"2019","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.vascn.2026.108419_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22011","article-title":"Development and validation of voriconazole concentration by LC-MS-MS: Applied in clinical implementation","volume":"31","author":"Prommas","year":"2017","journal-title":"Journal of Clinical Laboratory Analysis"},{"key":"10.1016\/j.vascn.2026.108419_bb0100","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jcph.741","article-title":"Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor","volume":"56","author":"Salem","year":"2016","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2024","key":"10.1016\/j.vascn.2026.108419_bb0105","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1016\/j.vascn.2026.108419_bb0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2020.01.003","article-title":"Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells","volume":"81","author":"Valdez","year":"2020","journal-title":"Experimental Hematology"},{"key":"10.1016\/j.vascn.2026.108419_bb0115","doi-asserted-by":"crossref","first-page":"220","DOI":"10.18632\/oncotarget.28563","article-title":"ABT199\/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells","volume":"15","author":"Valdez","year":"2024","journal-title":"Oncotarget"},{"key":"10.1016\/j.vascn.2026.108419_bb0120","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s12185-015-1853-6","article-title":"Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients","volume":"102","author":"Watanabe","year":"2015","journal-title":"International Journal of Hematology"},{"key":"10.1016\/j.vascn.2026.108419_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2024.102037","article-title":"Efficacy and safety of cladribine in combination with busulfan and cyclophosphamide as an intensive conditioning regimen preceding allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia","volume":"84","author":"Xiao","year":"2024","journal-title":"Transplant Immunology"},{"key":"10.1016\/j.vascn.2026.108419_bb0130","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3390\/molecules27051607","article-title":"Quantification of venetoclax for therapeutic drug monitoring in Chinese acute myeloid leukemia patients by a validated UPLC-MS\/MS method","volume":"27","author":"Yang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.vascn.2026.108419_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5738","article-title":"LC-MS\/MS methods for determination of venetoclax in human plasma and cerebrospinal fluid","volume":"37","author":"Yang","year":"2023","journal-title":"Biomedical Chromatography"},{"key":"10.1016\/j.vascn.2026.108419_bb0140","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1007\/s00277-023-05500-2","article-title":"Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms","volume":"102","author":"Zheng","year":"2023","journal-title":"Annals of Hematology"}],"updated-by":[{"DOI":"10.1016\/j.vascn.2026.108419","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000}}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871926000122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871926000122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:09:55Z","timestamp":1776352195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871926000122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":25,"alternative-id":["S1056871926000122"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2026.108419","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WITHDRAWN: Simultaneous quantification of venetoclax, busulfan and voriconazole in plasma by LC-MS\/MS: clinical applications in patients with acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2026.108419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108419"}}